Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

In this podcast episode, listen to Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, as they answer clinician questions from a live webinar covering the latest evidence for individualizing treatment of patients with HR-positive, HER2-negative early breast cancer.
Javier Cortes, MD, PhD
Stephen R. D. Johnston, MA, FRCP, PhD
Sara Tolaney, MD, MPH
Released: August 5, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Information on this Educational Activity

Faculty

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Athenex, Bioasis, Biothera, Boehringer Ingelheim, Celgene, Cellestia, Clovis Oncology, Daiichi Sankyo, Erytech, GlaxoSmithKline, Leuko, Lilly, Kyowa Kirin, Merck Sharp & Dohme, Merus, Polyphor, Roche, Seattle Genetics, and Servier; has received funds for research support from Ariad, AstraZeneca, Baxalta GmbH/Servier Affaires, Bayer, Eisai, F. Hoffmann-La Roche, Guardant, Merck Sharp & Dohme, Pfizer, Piqur, Puma, and Roche; has received fees for non-CME/CE services from Celgene, Daiichi Sankyo, Eisai, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Samsung Bioepis; has received other financial or material support from Daiichi Sankyo, Eisai, Novartis, Pfizer, and Roche; and has ownership interest in MedSIR.
Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Stephen R. D. Johnston, MA, FRCP, PhD, has disclosed that he has received consulting fees from AstraZeneca, Lilly, Novartis, Pfizer, and Puma Biotechnology; funds for research support from AstraZeneca, Lilly, Novartis, Pfizer, Puma, and Roche/ Genentech; and fees for non-CME/CE services from AstraZeneca, Eisai, Novartis, Pfizer, and Roche/Genentech.
Sara Tolaney, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician

Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support paid to her institution AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Immunomedics/Gilead Sciences, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and consulting fees from 4D Pharm, AstraZeneca, Athenex, Bristol-Myers Squibb, Certara, Cytom, Daiichi Sankyo, Eisai, Ellipses, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin, Lilly, Merck, Mersana, Nanostring, Nektar, Novartis, Odonate, OncoPep, Pfizer, Puma, Samsung Bioepsis, Sanofi, and Seattle Genetics.

Program Medium

This program has been made available online.

Related Content

In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see

Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: December 6, 2021

Laura M. Spring, MD, discusses the use of abemaciclib in patients with HR-positive, HER2-negative, node-positive early breast cancer, from Clinical Care Options (CCO)

Laura M. Spring, MD Released: November 29, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Expert podcast on second-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue